Price Chart

Headline
Wire
Time (ET)
SA Breaking News
12/16 04:37
SA Breaking News
12/10 04:18
No data available
DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
             
             
             
             
             
             
             
             

Earnings

Next Report Date --
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date --
Beat/Miss Upgrade
Return Since --
Last FQE 10/31/2021
Next FQE 01/31/2022

Profile

Edit
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
URL https://www.helixbiopharma.com
Investor Relations URL N/A
HQ State/Province Ontario
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
4.29%
-35.49%
-43.30%
-33.39%
169.5%
-58.46%
-40.44%
0.00%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-3.91%
-32.14%
-14.98%
115.7%
50.55%
197.1%
-31.74%
65.37%
-18.80%
-44.04%
-68.72%
-60.09%
-83.95%
-24.91%
3.66%
32.47%
-13.50%
47.27%
-31.65%
-37.82%
-81.28%
-95.69%
-49.88%
-74.05%
2.75%
-59.29%
-4.23%
-63.31%
123.4%
107.8%
17.32%
103.1%
-1.34%
As of January 18, 2022.

Profile

Edit
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
URL https://www.helixbiopharma.com
Investor Relations URL N/A
HQ State/Province Ontario
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release N/A
Last Earnings Release N/A
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits HBPCF Tweets